BRIEF-Coherus Biosciences regains development and commercial rights to CHS-0214 from Shire

Tue Sep 27, 2016 8:16am EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

Sept 27 (Reuters) - Coherus Biosciences Inc. :

* Says has regained from shire plc all development and commercial rights previously licensed for chs-0214 etanercept

* Coherus Biosciences regains development and commercial rights to CHS 0214 from Shire

* As result of termination agreement with Shire, co expects to recognize $162.6 million as collaboration and license revenues in 2016

* CHS-0214 etanercept is a biosimilar candidate to enbrel for Europe, Canada, Brazil, Middle East and other territories

* Remain on track for submission of a CHS-0214 marketing authorization application to european medicines agency in Q4 of 2016 Source text for Eikon: Further company coverage: